QARZIBA 4.5mg (Dinutuximab Vials) 4.5mg/ml x 20mg

QARZIBA 4.5mg (Dinutuximab) is a monoclonal antibody therapy used in pediatric oncology. This 4.5mg/ml vial formulation supports targeted treatment protocols. Store between 2-8°C to maintain potency. Consult healthcare provider for suitability.

Strength

4.5mg/ml x 20mg

Pack Size

Storage

2-8°

Manufacturer / TM Owner

Eusa Pharma

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Dinutuximab is primarily used in the treatment of high-risk neuroblastoma in pediatric patients. It targets GD2, a disialoganglioside expressed on neuroblastoma cells, helping to reduce tumor burden. This therapy is typically administered as part of a multi-drug regimen under medical supervision. Patients and caregivers often ask what QARZIBA 4.5mg is used for in cancer treatment protocols.

Side Effects

As a monoclonal antibody, Dinutuximab works by binding to specific antigens on cancer cells, marking them for immune system recognition. Common effects include infusion-related reactions such as fever, pain, or low blood pressure during administration. Some patients may experience fatigue or nausea, which are typically managed with supportive care.

Precautions & Warnings

QARZIBA 4.5mg requires careful handling and administration by healthcare professionals. Keep vials refrigerated between 2-8°C and protect from light. Avoid shaking the vial to prevent protein degradation. Patients should report any signs of infusion reactions immediately to their healthcare provider.

Avoid Interactions

Dinutuximab may interact with other medications that affect the immune system, such as corticosteroids or immunosuppressants. Live vaccines should be avoided during treatment due to potential reduced efficacy. Patients should inform their healthcare provider about all medications, including over-the-counter and herbal supplements, before starting Dinutuximab therapy.

Frequently Asked Questions

Dinutuximab is used to treat high-risk neuroblastoma in pediatric patients as part of a combination therapy.

QARZIBA 4.5mg is administered intravenously by healthcare professionals in a clinical setting.

Common side effects include infusion reactions like fever, pain, or low blood pressure, as well as fatigue or nausea.

No, QARZIBA 4.5mg must be administered by healthcare professionals in a controlled medical environment.

QARZIBA 4.5mg should be stored refrigerated between 2-8°C and protected from light.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.